annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *50 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*50 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *50 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *52 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*52 allele has been assigned as a no function allele by CPIC. Patients carrying the *52 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *55 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*55 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *55 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *6 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokin... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *8 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*8 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *8 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the phar... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047840 | rs761142 | rs761142 | GCLC | AA | 3 | Toxicity | sulfamethoxazole | HIV infectious disease | Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. | https://www.clinpgx.org/clinicalAnnotation/982047840 |
982047840 | rs761142 | rs761142 | GCLC | AC | 3 | Toxicity | sulfamethoxazole | HIV infectious disease | Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. | https://www.clinpgx.org/clinicalAnnotation/982047840 |
982047840 | rs761142 | rs761142 | GCLC | CC | 3 | Toxicity | sulfamethoxazole | HIV infectious disease | Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction. | https://www.clinpgx.org/clinicalAnnotation/982047840 |
982047849 | rs6280 | rs6280 | DRD3 | CC | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982047849 |
982047849 | rs6280 | rs6280 | DRD3 | CT | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982047849 |
982047849 | rs6280 | rs6280 | DRD3 | TT | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982047849 |
982047862 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 2A | Efficacy | captopril | Chronic Obstructive Pulmonary Disease;Diabetes Mellitus, Type 2;Heart Failure | Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotypes. However, con... | https://www.clinpgx.org/clinicalAnnotation/982047862 |
982047862 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 2A | Efficacy | captopril | Chronic Obstructive Pulmonary Disease;Diabetes Mellitus, Type 2;Heart Failure | Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and may have an increased response when treated with captopril as compared to patients with the del/del genotype, or a decreased response compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCA... | https://www.clinpgx.org/clinicalAnnotation/982047862 |
982047862 | rs1799752 | rs1799752 | ACE | del/del | 2A | Efficacy | captopril | Chronic Obstructive Pulmonary Disease;Diabetes Mellitus, Type 2;Heart Failure | Patients with the rs1799752 del/del genotype may have a decreased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotypes. However, conf... | https://www.clinpgx.org/clinicalAnnotation/982047862 |
982047910 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | enalapril | Arteriosclerosis;Coronary Disease;Essential hypertension;Glomerulonephritis, IGA;Kidney Disorder | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have decreased response when treated with enalapril as compared to patients with the del/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. Other genetic and clinical... | https://www.clinpgx.org/clinicalAnnotation/982047910 |
982047910 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | enalapril | Arteriosclerosis;Coronary Disease;Essential hypertension;Glomerulonephritis, IGA;Kidney Disorder | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may have decreased response when treated with enalapril as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to enalapril. | https://www.clinpgx.org/clinicalAnnotation/982047910 |
982047910 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | enalapril | Arteriosclerosis;Coronary Disease;Essential hypertension;Glomerulonephritis, IGA;Kidney Disorder | Patients with the del/del genotype may have increased response when treated with enalapril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical... | https://www.clinpgx.org/clinicalAnnotation/982047910 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.